Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 31, 2006

Dyax and ZymoGenetics Ink Library License Agreement

  • ZymoGenetics will use Dyax’ antibody phage display libraries to discover therapeutic antibodies according to a nonexclusive license.

    ZymoGenetics also received sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’ antibody phage display technology. Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, clinical milestone payments, and royalties on net sales of products that may result from this transaction.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »